Federal Capture Intelligence

Pharmaceutical Preparation Manufacturing contractors at the Department of Health and Human Services

Contract actions: October 1, 2021 – July 27, 2026 Updated July 28, 2026 Department of Health and Human Services agency guide NAICS 325412 · Pharmaceutical Preparation Manufacturing
Latest 12 months
$1.0B
Net obligations · Down $353.5M vs. $1.4B preceding
Prime contractors
62
With positive obligations in the latest 12 months

Market snapshot for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Federal records show $5.8B in net obligations across 1,142 awards in Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services from Oct 1, 2021 through Jul 27, 2026. This market accounts for 4.1% of $140.6B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations decreased 26.1% from $1.4B to $1.0B. 11 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Jul 27, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: $562.2M versus $676.0M through the same date in FY25 (−16.8%).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B493Complete
FY2023$1.1B492Complete
FY2024$913.1M418Complete
FY2025$1.1B360Complete
FY2026$562.2M219YTD through Jul 27, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$5.8B
1,142 awards · 203 prime contractors
Latest 12-month movement
−26.1%
$1.0B vs. $1.4B
Leading eight prime share
69.2%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
4.1% of $140.6B in agency-wide net obligations.
Set-aside share when reported
8.0% of 499 awards with reported set-aside status.
Set-aside reporting
40 set aside · 459 no set-aside · 643 not reported

What changed in the last 12 months?

Jul 28, 2025–Jul 27, 2026, compared with Jul 28, 2024–Jul 27, 2025.

Buyer demand

Reported obligations through BARDA - ASPR / DAAPPO / BARDA DCMA decreased
$531.8M→$159.8M−$371.9M
Latest-period activity spans 11 awards across 10 prime contractors.
Reported obligations through INDIAN HEALTH SERVICE increased
$33.1M→$156.3M+$123.2M
Latest-period activity spans 35 awards across 5 prime contractors.

Competitive shifts

MERCK SHARP & DOHME LLC lost the most market share
9.0%→0.3%−8.7 percentage points
The contractor now ranks #24 by positive obligations, based on 3 reported actions.
ALVOGEN, INC. had no reported activity in the latest 12 months
$284.8M→$0No latest-period activity
It previously ranked #2 by positive obligations, based on 4 reported actions.
GLAXOSMITHKLINE, LLC climbed the most in the contractor rankings
#53→#15Up 38 places
The contractor accounts for 1.8% of positive obligations across 6 reported actions.

Market structure

Top-five contractor share decreased
66.2%→53.6%−12.6 percentage points
Contractors outside the top five now account for 46.4% of positive obligations.
View 2 additional material changes

Competitive shifts

PHLOW CORP. gained the most market share
4.8%→11.3%+6.5 percentage points
The contractor now ranks #3 by positive obligations, based on 18 reported actions.
ELUSYS THERAPEUTICS INC had the largest increase in reported obligations
$0→$55.3M+$55.3M
The contractor now ranks #6 by positive obligations and accounts for 5.5% of positive obligations, based on 4 reported actions.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Funding pattern for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

See how positive obligations were attributed across funding offices in the 12 months ending Jul 27, 2026.

44.0% of positive obligations were attributed to ASPR/ORM-SNS. That represents $450.3M, up $83.8M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. ASPR/ORM-SNS44.0% · $450.3M · up $83.8M
  2. BARDA - ASPR / DAAPPO / BARDA DCMA15.6% · $159.8M · down $371.9M
  3. INDIAN HEALTH SERVICE15.3% · $156.3M · up $123.2M
  4. ASPR/DAAPPO/ORM HQ11.1% · $113.8M · up $112.7M
  5. NATIONAL INSTITUTES OF HEALTH OLAO6.4% · $65.2M · up $65.2M
  6. All other reported offices7.5% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    ASPR/ORM-SNS

    #1Up 1 from #2

    Latest 12 months

    $450.3M

    44.0% of positive obligations

    Versus preceding 12 months

    +$83.8M

    18 active prime contractors · 21 awards

    View office comparison and evidence

    Reported obligations increased 22.9% from $366.5M to $450.3M. The office’s share of positive obligations moved from 27.0% to 44.0%, a change of +17.0 percentage points.

    The latest period contains 36 actions across 21 awards and 9 newly active prime contractors. The preceding period contained 17 active prime contractors and 24 awards.

  2. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #2Down 1 from #1

    Latest 12 months

    $159.8M

    15.6% of positive obligations

    Versus preceding 12 months

    −$371.9M

    10 active prime contractors · 11 awards

    View office comparison and evidence

    Reported obligations decreased 69.9% from $531.8M to $159.8M. The office’s share of positive obligations moved from 39.2% to 15.6%, a change of −23.6 percentage points.

    The latest period contains 11 actions across 11 awards and 6 newly active prime contractors. The preceding period contained 11 active prime contractors and 11 awards.

    Leading award-level changes

  3. Reported funding office

    INDIAN HEALTH SERVICE

    #3Up 5 from #8

    Latest 12 months

    $156.3M

    15.3% of positive obligations

    Versus preceding 12 months

    +$123.2M

    5 active prime contractors · 35 awards

    View office comparison and evidence

    Reported obligations increased 372.0% from $33.1M to $156.3M. The office’s share of positive obligations moved from 2.4% to 15.3%, a change of +12.8 percentage points.

    The latest period contains 36 actions across 35 awards and 1 newly active prime contractor. The preceding period contained 6 active prime contractors and 23 awards.

    Leading award-level changes

  4. Reported funding office

    ASPR/DAAPPO/ORM HQ

    #4Up 10 from #14

    Latest 12 months

    $113.8M

    11.1% of positive obligations

    Versus preceding 12 months

    +$112.7M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations increased 9869.3% from $1.1M to $113.8M. The office’s share of positive obligations moved from 0.080% to 11.1%, a change of +11.1 percentage points.

    The latest period contains 19 actions across 2 awards. The preceding period contained 2 active prime contractors and 8 awards.

  5. Reported funding office

    NATIONAL INSTITUTES OF HEALTH OLAO

    #5New to the positive-obligation ranking

    Latest 12 months

    $65.2M

    6.4% of positive obligations

    Versus preceding 12 months

    +$65.2M

    5 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations moved from $6K in net deobligations to $65.2M in net obligations. The office’s share of positive obligations moved from 0% to 6.4%, a change of +6.4 percentage points.

    The latest period contains 8 actions across 7 awards and 5 newly active prime contractors. The preceding period contained 1 active prime contractor and 1 award.

  6. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #6Rank unchanged

    Latest 12 months

    $51.2M

    5.0% of positive obligations

    Versus preceding 12 months

    −$10.6M

    3 active prime contractors · 3 awards

    View office comparison and evidence

    Reported obligations decreased 17.2% from $61.8M to $51.2M. The office’s share of positive obligations moved from 4.6% to 5.0%, a change of +0.5 percentage points.

    The latest period contains 11 actions across 3 awards and 1 newly active prime contractor. The preceding period contained 6 active prime contractors and 6 awards.

  7. Reported funding office

    PHOENIX AREA INDIAN HEALTH SVC

    #7Rank unchanged

    Latest 12 months

    $17.3M

    1.7% of positive obligations

    Versus preceding 12 months

    −$36.4M

    6 active prime contractors · 16 awards

    View office comparison and evidence

    Reported obligations decreased 67.7% from $53.7M to $17.3M. The office’s share of positive obligations moved from 4.0% to 1.7%, a change of −2.3 percentage points.

    The latest period contains 20 actions across 16 awards. The preceding period contained 6 active prime contractors and 32 awards.

  8. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #8Up 4 from #12

    Latest 12 months

    $1.8M

    0.17% of positive obligations

    Versus preceding 12 months

    −$39K

    2 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations decreased 2.1% from $1.8M to $1.8M. The office’s share of positive obligations moved from 0.13% to 0.17%, a change of 0.0 percentage points.

    The latest period contains 4 actions across 4 awards. The preceding period contained 2 active prime contractors and 4 awards.

  9. Reported funding office

    NATIONAL INSTITUTES OF HEALTH - CC

    #9Down 5 from #4

    Latest 12 months

    $1.7M

    0.17% of positive obligations

    Versus preceding 12 months

    −$97.4M

    22 active prime contractors · 32 awards

    View office comparison and evidence

    Reported obligations decreased 98.2% from $99.2M to $1.7M. The office’s share of positive obligations moved from 7.3% to 0.17%, a change of −7.1 percentage points.

    The latest period contains 39 actions across 32 awards and 11 newly active prime contractors. The preceding period contained 22 active prime contractors and 72 awards.

  10. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIDA

    #10Up 15 from #25

    Latest 12 months

    $991K

    0.10% of positive obligations

    Versus preceding 12 months

    +$980K

    8 active prime contractors · 14 awards

    View office comparison and evidence

    Reported obligations increased 8890.6% from $11K to $991K. The office’s share of positive obligations moved from 0% to 0.10%, a change of +0.1 percentage points.

    The latest period contains 15 actions across 14 awards and 5 newly active prime contractors. The preceding period contained 5 active prime contractors and 9 awards.

  11. Reported funding office

    INDUSTRIAL BASED MANUFACTURING AND SUPPLY CHAIN (IBMSC)

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    −$80.9M

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations decreased 100.0% from $80.9M to $0. The office’s share of positive obligations moved from 6.0% to 0%, a change of −6.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 2 active prime contractors and 2 awards.

  12. Reported funding office

    NAVAJO AREA INDIAN HEALTH SVC

    No positive-obligation rank

    Latest 12 months

    −$18.6M

    0% of positive obligations

    Versus preceding 12 months

    −$133.5M

    8 active prime contractors · 28 awards

    View office comparison and evidence

    Reported obligations moved from $115.0M in net obligations to $18.6M in net deobligations. The office’s share of positive obligations moved from 8.5% to 0%, a change of −8.5 percentage points.

    The latest period contains 36 actions across 28 awards and 5 newly active prime contractors. The preceding period contained 7 active prime contractors and 50 awards.

How this work is bought

Reported award structure, competition, pricing, work categories, and contracting channels for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services.

During Jul 28, 2025–Jul 27, 2026, this market recorded $1.1B in positive net award obligations across 125 awards. The leading reported procedure, Only One Source, accounted for 46.0% of that positive-obligation base. Awards with a reported parent IDV accounted for 37.4%.

Leading award type
62.3%
Definitive Contract
Leading reported procedure
46.0%
Only One Source
Reported parent IDV
37.4%
of positive obligations had a reported parent IDV
Median reported offers
1
73 of 125 awards reported offers

Same-NAICS comparison

Compared with the NAICS 325412 peer median, parent-IDV obligation share is 60.6 percentage points lower, reported full-and-open obligation share is 44.2 percentage points lower, delivery-order obligation share is 60.4 percentage points lower, and median positive award obligations are 4364.8% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share37.4%98.0%-60.6 pts
Reported full-and-open obligation share53.5%97.7%-44.2 pts
Delivery-order obligation share37.3%97.8%-60.4 pts
Median positive award obligations$543K$12K+4364.8%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)21$666.8M62.3%
Delivery Order(C)72$399.5M37.3%
Purchase Order(B)27$3.1M0.29%
BPA Call(A)5$950K0.090%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
FSS(C)15$215.8M20.2%
IDC(B)57$183.7M17.2%
BPA(E)5$950K0.090%
Not reported48$670.0M62.6%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Multiple Award(M)21$219.1M20.5%
Single Award(S)56$181.4M16.9%
Not reported48$670.0M62.6%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Only One Source(SSS)13$492.7M46.0%
Negotiated Proposal/Quote(NP)55$354.4M33.1%
Subject To Multiple Award Fair Opportunity(MAFO)20$218.9M20.4%
Simplified Acquisition(SP1)36$4.2M0.39%
Two Step(TS)1$300K0.030%

Extent competed

Reported valueAwardsPositive obligationsShare
Full And Open Competition(A)73$572.7M53.5%
Not Competed(C)13$492.7M46.0%
Competed Under SAP(F)26$2.4M0.23%
Not Competed Under SAP(G)10$1.8M0.17%
Full And Open Competition After Exclusion Of Sources(D)3$908K0.080%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Only One Source - Other(ONE)10$96.4M9.0%
Competitive Set Aside(CSA)1$57.7M5.4%
Fair Opportunity Given(FAIR)7$34.7M3.2%
Urgency(URG)1$30.0M2.8%
Other Statutory Authority(OSA)1$127K0.010%
Not reported105$851.6M79.5%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)10$270.0M25.2%
Mobilization, Essential R&d (FAR 6.302-3)(MES)2$168.9M15.8%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$53.7M5.0%
SAP Non-Competition (FAR 13)(SP2)8$1.7M0.16%
Authorized By Statute (FAR 6.302-5(A)(2)(I))(OTH)1$50K0%
Less Than Or Equal To The Micro-Purchase Threshold(MPT)1$3K0%
Not reported102$576.0M53.8%

Contract pricing types

Reported valueAwardsPositive obligationsShare
Firm Fixed Price(J)117$944.6M88.2%
Cost Plus Fixed Fee(U)7$124.8M11.7%
Cost Plus Award Fee(R)1$1.1M0.10%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Drugs And Biologicals(6505)97$790.8M73.9%
R&d- Medical: Biomedical (Commercialized)(AN17)1$113.6M10.6%
Chemical And Pharmaceutical Products Manufacturing Machinery(3650)6$51.8M4.8%
Support- Administrative: Mailing/Distribution(R604)1$51.1M4.8%
Medical And Surgical Instruments, Equipment, And Supplies(6515)4$50.2M4.7%
Health R&d Services; Health Care Services; Basic Research(AN11)1$8.7M0.81%
Other reported values15$4.3M0.41%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)25$765.6M71.5%
Indian Health Service(7527)56$179.3M16.8%
National Institutes of Health(7529)34$72.4M6.8%
Centers for Disease Control and Prevention(7523)3$51.2M4.8%
Departmental Offices(1406)1$740K0.070%
Office of the Assistant Secretary for Administration(7570)3$720K0.070%
Other reported values3$511K0.048%

Awarding offices

Reported valueAwardsPositive obligationsShare
Aspr/Orm-Sns(75A503)20$543.3M50.8%
Indian Health Service(75H711)27$156.7M14.6%
Aspr/Daappo/Orm Hq(75A502)2$113.8M10.6%
Barda - Aspr / Daappo / Barda Dcma(75A501)3$108.5M10.1%
National Institutes Of Health Olao(75N980)10$66.2M6.2%
Cdc Office Of Acquisition Services(75D301)3$51.2M4.8%
Other reported values60$30.8M2.9%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
36W79720D0001(3600)38$168.3M15.7%
36F79720D0198(3600)1$57.7M5.4%
36F79723D0171(3600)1$50.0M4.7%
36F79723D0219(3600)1$37.5M3.5%
36F79723D0101(3600)1$30.0M2.8%
36F79724D0107(3600)1$16.6M1.6%
36F79720D0237(3600)1$15.1M1.4%
V797D70258(3600)1$8.1M0.76%
Other reported values32$17.2M1.6%
Not reported48$670.0M62.6%

Exactly matched vehicle usage

5 awards matched an unambiguous catalog vehicle PIID. Company membership is not used as evidence of award-channel usage.

Offers, award size, and timing

Median reported offers
1 median
73 reported · 52 not reported
Positive award obligations
$543K median
$92K–$5.4M middle 50%
Reported performance period
364 days (~12 months) median
125 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Jul 27, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Prime contractors for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Latest 12-month concentration and complete prime contractor rankings across the period shown.

Prime contractor concentration
11 of 62prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
14.4%of positive obligations in the last 12 months
Leading four prime contractors
47.1%of positive obligations in the last 12 months
Leading eight prime contractors
69.2%of positive obligations in the last 12 months

Based on $1.0B in positive obligations during the 12 months ending Jul 27, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Jul 28, 2024–Jul 27, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $144.4M

    14.4%

    Dollar movement

    −$61.4M

    vs. prior 12 months

    Last 12mo awards

    56 awards

    63 actions

    Historical and award details for MCKESSON CORPORATION
    Obligations: prior → latest
    $205.9M → $144.4M
    −29.8%
    Share: prior → latest
    12.1% → 14.4%
    +2.3 percentage points
    All-period obligations
    $729.0M
    12.6% of all-period positive obligations · 363 awards
    Recorded activity
    Since Oct 26, 2021
    through Jul 13, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside15
    Not reported5576
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $118.3M

    11.8%

    Dollar movement

    +$4.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for EMERGENT BIOSOLUTIONS CANADA INC
    Obligations: prior → latest
    $114.3M → $118.3M
    +3.5%
    Share: prior → latest
    6.7% → 11.8%
    +5.0 percentage points
    All-period obligations
    $558.4M
    9.7% of all-period positive obligations · 2 awards
    Recorded activity
    Since Oct 22, 2021
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $113.6M

    11.3%

    Dollar movement

    +$32.7M

    vs. prior 12 months

    Last 12mo awards

    1 award

    18 actions

    Historical and award details for PHLOW CORP.
    Obligations: prior → latest
    $80.9M → $113.6M
    +40.5%
    Share: prior → latest
    4.8% → 11.3%
    +6.5 percentage points
    All-period obligations
    $342.4M
    5.9% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 16, 2021
    through Jul 2, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $97.0M

    9.7%

    Dollar movement

    −$269.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for BAVARIAN NORDIC A/S
    Obligations: prior → latest
    $366.5M → $97.0M
    −73.5%
    Share: prior → latest
    21.6% → 9.7%
    −11.9 percentage points
    All-period obligations
    $882.1M
    15.3% of all-period positive obligations · 1 award
    Recorded activity
    Since May 17, 2022
    through May 11, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $65.5M

    6.5%

    Dollar movement

    −$32.6M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for DLA TROOP SUPPORT
    Obligations: prior → latest
    $98.1M → $65.5M
    −33.2%
    Share: prior → latest
    5.8% → 6.5%
    +0.7 percentage points
    All-period obligations
    $399.7M
    6.9% of all-period positive obligations · 10 awards
    Recorded activity
    Since Oct 18, 2021
    through Apr 17, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $55.3M

    5.5%

    Dollar movement

    +$55.3M

    vs. prior 12 months

    Last 12mo awards

    1 award

    4 actions

    Historical and award details for ELUSYS THERAPEUTICS INC
    Obligations: prior → latest
    $0 → $55.3M
    Not comparable
    Share: prior → latest
    0% → 5.5%
    +5.5 percentage points
    All-period obligations
    $153.7M
    2.7% of all-period positive obligations · 3 awards
    Recorded activity
    Since Nov 10, 2021
    through Jul 7, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $51.1M

    5.1%

    Dollar movement

    −$10.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    9 actions

    Historical and award details for MCKESSON SPECIALTY DISTRIBUTION LLC
    Obligations: prior → latest
    $61.7M → $51.1M
    −17.1%
    Share: prior → latest
    3.6% → 5.1%
    +1.4 percentage points
    All-period obligations
    $579.2M
    10.0% of all-period positive obligations · 2 awards
    Recorded activity
    Since Aug 2, 2022
    through Jun 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $50.0M

    5.0%

    Dollar movement

    −$11.3M

    vs. prior 12 months

    Last 12mo awards

    1 award

    3 actions

    Historical and award details for PARTNER THERAPEUTICS, INC.
    Obligations: prior → latest
    $61.3M → $50.0M
    −18.5%
    Share: prior → latest
    3.6% → 5.0%
    +1.4 percentage points
    All-period obligations
    $192.5M
    3.3% of all-period positive obligations · 3 awards
    Recorded activity
    Since Feb 15, 2022
    through Jun 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $46.0M

    4.6%

    Dollar movement

    +$9.4M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for MERIDIAN MEDICAL TECHNOLOGIES, LLC
    Obligations: prior → latest
    $36.6M → $46.0M
    +25.8%
    Share: prior → latest
    2.2% → 4.6%
    +2.4 percentage points
    All-period obligations
    $92.6M
    1.6% of all-period positive obligations · 3 awards
    Recorded activity
    Since Sep 22, 2023
    through Jan 5, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside10
    Reported no set-aside11
    Not reported00
    Reported small business10
    All-period set-aside types
    • 1 · Total small business
  10. #10

    Last 12mo obligations

    $37.5M

    3.7%

    Dollar movement

    +$367.4M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for GENENTECH USA, INC
    Obligations: prior → latest
    −$329.9M → $37.5M
    Not comparable
    Share: prior → latest
    0% → 3.7%
    +3.7 percentage points
    All-period obligations
    $164.6M
    2.9% of all-period positive obligations · 5 awards
    Recorded activity
    Since Sep 7, 2022
    through Mar 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported24
    Reported small business00
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $36.3M

    3.6%

    Dollar movement

    −$13.7M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for FRESENIUS KABI, LLC
    Obligations: prior → latest
    $50.0M → $36.3M
    −27.5%
    Share: prior → latest
    2.9% → 3.6%
    +0.7 percentage points
    All-period obligations
    $91.0M
    1.6% of all-period positive obligations · 2 awards
    Recorded activity
    Since Feb 28, 2023
    through Sep 11, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $33.1M

    3.3%

    Dollar movement

    −$7.9M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    7 actions

    Historical and award details for CHARTWELL RX LLC
    Obligations: prior → latest
    $41.0M → $33.1M
    −19.2%
    Share: prior → latest
    2.4% → 3.3%
    +0.9 percentage points
    All-period obligations
    $222.4M
    3.9% of all-period positive obligations · 4 awards
    Recorded activity
    Since Sep 26, 2022
    through Mar 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside22
    Reported no set-aside10
    Not reported00
    Reported small business22
    All-period set-aside types
    • 2 · Total small business
  13. #13

    Last 12mo obligations

    $30.0M

    3.0%

    Dollar movement

    +$30.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for USANTIBIOTICS LLC
    Obligations: prior → latest
    $0 → $30.0M
    Not comparable
    Share: prior → latest
    0% → 3.0%
    +3.0 percentage points
    All-period obligations
    $30.0M
    0.52% of all-period positive obligations · 1 award
    Recorded activity
    Since May 27, 2026
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business10
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $20.9M

    2.1%

    Dollar movement

    +$20.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for RAFA LABORATORIES LTD
    Obligations: prior → latest
    $0 → $20.9M
    Not comparable
    Share: prior → latest
    0% → 2.1%
    +2.1 percentage points
    All-period obligations
    $20.9M
    0.36% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 30, 2025
    through Sep 30, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $18.1M

    1.8%

    Dollar movement

    +$18.1M

    vs. prior 12 months

    Last 12mo awards

    5 awards

    6 actions

    Historical and award details for GLAXOSMITHKLINE, LLC
    Obligations: prior → latest
    $882 → $18.1M
    +2050775.8%
    Share: prior → latest
    0% → 1.8%
    +1.8 percentage points
    All-period obligations
    $36.5M
    0.63% of all-period positive obligations · 25 awards
    Recorded activity
    Since Oct 19, 2021
    through Jun 23, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported41
    Reported small business00
    All-period set-aside types

    None reported.

Recompete watch for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

BAVARIAN NORDIC A/S

BAVARIAN NORDIC MOD 21

$1.26B is obligated on an award with a reported potential end date of September 26, 2027.

Performance period

88.3%

As of Jul 27, 2026Potential end Sep 26, 2027

Current award value as a share of potential value

73.9%

$1.3B current$1.7B potential
Supporting data

Reported performance starts Sep 27, 2017.

No later potential end date is reported; current and potential end dates are both Sep 26, 2027.

$1.3B is obligated against $1.3B in current reported award value (100.0%).

Reported potential end dates: Sep 26, 2026 → Sep 26, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700019C

PARTNER THERAPEUTICS, INC.

EXERCISE OPTIONAL ORDERING PERIOD 2 FOR LEUKINE 250MCG VIAL INJECTABLES

$133.5M is obligated on an award with a reported potential end date of March 29, 2027.

Performance period

80.9%

As of Jul 27, 2026Potential end Mar 29, 2027

Current award value as a share of potential value

100.0%

$133.5M current$133.5M potential
Supporting data

Reported performance starts Sep 26, 2023.

No later potential end date is reported; current and potential end dates are both Mar 29, 2027.

$133.5M is obligated against $133.5M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Sep 29, 2027 → Mar 29, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50323F80027

ALVOGEN, INC.

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.

$227.7M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

53.8%

As of Jul 27, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$227.7M current$227.7M potential
Supporting data

Reported performance starts Jun 30, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$227.7M is obligated against $227.7M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80013

BAXTER HEALTHCARE CORPORATION

PRALIDOXIME CHLORIDE (PROTOPAM)

$39.2M is obligated on an award with a reported potential end date of September 29, 2026.

Performance period

96.5%

As of Jul 27, 2026Potential end Sep 29, 2026

Current award value as a share of potential value

75.1%

$39.2M current$52.2M potential
Supporting data

Reported performance starts Sep 30, 2021.

Current performance is reported through Sep 29, 2025.

$39.2M is obligated against $39.2M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Dec 27, 2022 → Sep 29, 2024 → Sep 29, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50121C00084

DLA TROOP SUPPORT

PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472]

$65.0M is obligated on an award with a reported potential end date of April 9, 2027.

Performance period

29.7%

As of Jul 27, 2026Potential end Apr 9, 2027

Current award value as a share of potential value

100.0%

$65.0M current$65.0M potential
Supporting data

Reported performance starts Apr 10, 2026.

No later potential end date is reported; current and potential end dates are both Apr 9, 2027.

$65.0M is obligated against $65.0M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N98026C00026

EXELAN PHARMACEUTICALS INC

OSELTAMIVIR PHOSPHATE 30MG CAPSULES CHANGE NDC FROM NDC 47781-468-13 TO NDC: 76282-0702-45); 10 CT. CAPSULES PACKS.

$74.1M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

53.9%

As of Jul 27, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$74.1M current$74.1M potential
Supporting data

Reported performance starts Jun 28, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$74.1M is obligated against $74.1M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80014

These are research leads, not confirmed recompetes. USAspending records through Jul 27, 2026; reported dates and values can change through later modifications.

Award activity for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Modification

This action

+$53.9M

PHLOW CORP.

ASPR/DAAPPO/ORM HQ

THE PURPOSE OF THIS ACTION IS TO FUND THE REMAINING APIS FOR THE STRATEGIC RESERVE

Why it stands out

The contractor climbed 4 positions in this market.

It now ranks #3 by positive obligations over the latest 12 months.

Award net obligations
$696.7M
Share of 12-month positive obligations
5.4%
Supporting data
Prime contractor
#3 · 11.3% share
up 4 ranks · +6.5 percentage points · $32.7M net increase; action exceeded it by $21.2M
Funding office
#4 · 11.1% attributed share
up 10 ranks · +11.1 percentage points · $112.7M net increase; action accounted for 47.8%
Related:Largest share gain
PIID 75A50120C00092 · Mod P00027
Modification

This action

+$55.3M

ELUSYS THERAPEUTICS INC

ASPR/ORM-SNS

ANTHIM (OBILTOXAXIMAB)

Why it stands out

The award grew alongside stronger contractor activity.

The modification added $55.3M while contractor obligations rose $55.3M overall.

Award net obligations
$124.5M
Share of 12-month positive obligations
5.5%
Supporting data
Prime contractor
#6 · 5.5% share
+5.5 percentage points · $55.3M net increase; action accounted for 100.0%
Related:Largest contractor gain
PIID 75A50324C00006 · Mod P00004
Modification

This action

+$64.5M

EMERGENT BIOSOLUTIONS CANADA INC

ASPR/ORM-SNS

EO14042 BOTULISM ANTITOXIN

Why it stands out

The contractor climbed 3 positions in this market.

It now ranks #2 by positive obligations over the latest 12 months.

Award net obligations
$320.9M
Share of 12-month positive obligations
6.4%
Supporting data
Funding office
#1 · 44.0% attributed share
up 1 rank · +17.0 percentage points · $83.8M net increase; action accounted for 77.0%
PIID 75A50119C00075 · Mod P00015
Modification

This action

+$97.0M

BAVARIAN NORDIC A/S

BARDA - ASPR / DAAPPO / BARDA DCMA

BAVARIAN NORDIC MOD 21

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $97.0M while office-attributed obligations fell $371.9M overall.

Award net obligations
$1.3B
Share of 12-month positive obligations
9.7%
Supporting data
Prime contractor
#4 · 9.7% share
$269.5M net decline despite this positive action
Funding office
#2 · 15.6% attributed share
$371.9M net decline despite this positive action
PIID HHSO100201700019C · Mod P00021
Modification

This action

+$50.0M

DLA TROOP SUPPORT

NATIONAL INSTITUTES OF HEALTH OLAO

PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472]

Why it stands out

The award grew alongside stronger office-attributed spending.

The modification added $50.0M while office-attributed obligations rose $65.2M overall.

Award net obligations
$65.0M
Share of 12-month positive obligations
5.0%
Supporting data
Prime contractor
#5 · 6.5% share
$32.6M net decline despite this positive action
Funding office
#5 · 6.4% attributed share
+6.4 percentage points · $65.2M net increase; action accounted for 76.7%
PIID 75N98026C00026 · Mod P00001
Base award

This action

+$30.0M

USANTIBIOTICS LLC

ASPR/ORM-SNS

AMOXICILLIN TRIHYDRATE 500MG 60 CT AND 100 CT ORAL CAPSULES

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #13 in this market by positive obligations over the latest 12 months.

Award net obligations
$30.0M
Share of 12-month positive obligations
3.0%
Supporting data
Prime contractor
#13 · 3.0% share
Newly active in this market; no actions were reported in the preceding 12 months
PIID 75A50326F80004
View recent award activity by date (10)
  1. MCKESSON CORPORATIONDeobligation · PIID 75H71024F80293
    Action−$30K
    Award net obligations$30K
  2. SEQIRUS USA INCBase award · PIID 75H71126F80043
    Action+$2.7M
    Award net obligations$2.7M
  3. PINE PHARMACEUTICALS LLCBase award · PIID 75N98026F00003
    Action+$411K
    Award net obligations$411K
  4. CARDINAL HEALTH, INC.Base award · PIID 75N98026P00852
    Action+$42K
    Award net obligations$42K
  5. ELUSYS THERAPEUTICS INCModification · PIID 75A50324C00006
    Action+$9.6M
    Award net obligations$124.5M
  6. ADVANCED CELL DIAGNOSTICS, INC.Deobligation · PIID 75N91021P00473
    Action−$14K
    Award net obligations$10K
  7. MRIGLOBALDeobligation · PIID 75N95019F00088
    Action−$1K
    Award net obligations$2.4M
  8. MRIGLOBALDeobligation · PIID HHSN27100001
    Action−$778
    Award net obligations$515K
  9. GLAXOSMITHKLINE, LLCModification · PIID 75A50325C00019
    Action+$9.1M
    Award net obligations$18.2M
  10. VALNEVA USA, INC.Base award · PIID 7571MN26P00043
    Action+$170K
    Award net obligations$120K

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Reported obligations include contract actions from October 1, 2021 through July 27, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology